JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia

ASWAD, Mohamed Hussam, Jarmila KISSOVÁ, Petra OVESNÁ, Lucie ŘÍHOVÁ and Miroslav PENKA. JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia. CLINICAL HEMORHEOLOGY AND MICROCIRCULATION. AMSTERDAM: IOS PRESS, 2023, vol. 84, No 4, p. 359-368. ISSN 1386-0291. Available from: https://dx.doi.org/10.3233/CH-221678.

Basic information

• Original name: JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia
• Authors: ASWAD, Mohamed Hussam (760 Syrian Arab Republic, guarantor, belonging to the institution), Jarmila KISSOVÁ (203 Czech Republic, belonging to the institution), Petra OVESNÁ (203 Czech Republic, belonging to the institution), Lucie ŘÍHOVÁ (203 Czech Republic, belonging to the institution) and Miroslav PENKA (203 Czech Republic, belonging to the institution).
• Edition: CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, AMSTERDAM, IOS PRESS, 2023, 1386-0291.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30205 Hematology
• Country of publisher: Netherlands
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 2.100 in 2022
• RIV identification code: RIV/00216224:14110/23:00130986
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.3233/CH-221678
• UT WoS: 001076811500002
• Keywords in English: Essential thrombocythemia; thrombosis; risk factor; JAK2V617F mutation; extracellular vesicles
• Tags: 14110212, 14119612, rivok
• Tags: International impact, Reviewed

Abstract

The clinical course of essential thrombocythemia (ET) is complicated with thrombosis which significantly impacts patients’ mortality. Studies have identified JAK2V617F mutation as an independent risk factor for thrombosis. Circulating extracellular vesicles (EVs) were evaluated in several studies regarding myeloproliferative neoplasms and thrombosis as potential biomarkers. The present study investigates the relationship between JAK2V617F mutation and EVs levels in 119 ET patients. Our analyses revealed that JAK2V617F-positive patients are at a significantly increased risk of thrombosis within five years before the ET diagnosis (hazard ratio [95% CI]: 11.9 [1.7–83.7], P = 0.013), and that JAK2V617F mutation is an independent risk factor for thrombosis at ET diagnosis or during the follow-up (hazard ratio [95% CI]: 3.56 [1.47–8.62], P = 0.005). ET patients have higher levels of platelet-EVs, erythrocyte-EVs and procoagulant activity of EVs than the healthy population. Absolute and relative counts of platelet-EVs are increased in the presence of JAK2V617F mutation (P = 0.018, P = 0.024, respectively). In conclusion, our results support the role of JAK2V617F mutation in the pathogenesis of thrombosis in essential thrombocythemia through enhancing platelet activation.